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month and cost/ OS month gained over control for each treatment, across the 
EU5, were then calculated. Results: Based on total OS, docetaxel consistently 
offered the lowest cost/OS month across the EU5 with a median cost of € 531/ OS 
month. For post-chemotherapy indications, Zytiga had the highest cost/OS month 
(€ 1820-€ 2904) in all countries except Italy, where Xtandi was higher (€ 3620). In 
contrast, for the pre-chemotherapy indications ,Xtandi had the highest cost/OS 
month (€ 1839 - € 4112) across the EU5. When comparing price/OS month gained 
over control, there was significant variation across products. For example, the 
EU5 median cost/OS month were significantly higher for the pre-chemotherapy 
indications for Zytiga and Xtandi (€ 12,869 and € 27,281 respectively) versus their 
post-chemotherapy indications (€ 7136 and € 6252 respectively). Jevtana’s EU5 
median cost of € 11,322, for post-chemotherapy, was comparable to the cost/OS 
month gained over control for the pre-chemotherapy indications of Zytiga and 
Xtandi. ConClusions: Payers do not equally value cost/OS month, as observed 
by the range of costs/OS month across products. Similarly, there is significant 
variation in the price/OS month gained over control, with payers paying signifi-
cantly more for the pre-chemotherapy compared to post-chemotherapy indica-
tions, inferring that payers maybe willing to pay more for treatments earlier in 
the treatment pathway for mCRPC.
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objeCtives: To analyze budget impact and determine cost-effectiveness of differ-
ent strategies of hemostasis during hepatic resection in patients with benign and 
malignant tumors. Methods: A pharmacoeconomic model of application of differ-
ent strategies of hemostasis in target population of patients was created based on 
the data of clinical study by J. Briceño et al. (2010). Two groups of patient (100 persons 
each) were considered: 1st with tachocomb fibrin-coated collagen fleece, and 2nd 
with alternative hemostatic technologies (standard care). The calculation included 
direct costs of pharmacotherapy with different hemostatic strategies, cost of stay 
in hospital, costs of hepatectomy, and costs of blood transfusion. Results: Total 
costs were significantly lower in the group of fibrin-coated collagen fleece compared 
with the group of standard care (8,502,298.53 RUB vs. 9,243,846.02 RUB, respectively). 
Analysis of budget items showed that costs of hospitalization were 3,952,000 RUB 
in tachocomb group, and 5,200,000 RUB in the control group. In addition, the use of 
fibrin-coated collagen fleece reduced the financial costs of blood transfusion nearly 
threefold (456,146.02 RUB and 124,598.53 RUB, respectively). Cost-effectiveness ratio 
defined as a number of patients with no complications after minor or extensive 
hepatic resection was 135,938.91 and 111,872.35 in the standard care group and 
tachocomb group, respectively. ConClusions: Pharmacoeconomic advantages 
were established for the strategy with application of tachocomp fibrin-coated col-
lagen fleece during hepatectomy of patients with for benign and malignant tumors. 
The benefits were connected with lower financial costs and more favorable cost-
effectiveness.
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objeCtives: To compare the cost associated with advanced breast cancer treated 
with vinorelbine oral (VinO) versus IV (VinIV) from the national health services 
perspective in France. Methods: This was an observational, prospective, inter-
national, multicentric study. This analysis focused on French patients who were 
included in the study at the beginning of their 2nd cycle of chemotherapy with 
vinorelbine and categorized in 2 groups depending on whether they are receiving 
VinO or VinIV. In and out-patient resource utilization was collected during two 
cycles. The analysis was conducted according to the recommendations published 
by the Haute Autorité de la Santé. Results are expressed in euros 2014. The economic 
perspective is the one of the Sécurité Sociale. Results: 43 patients received VinO 
and 8 VinIV. No major difference was found between the two groups on the main 
known economics-related confounding factors. Median cost for transportation was 
lower in the VinO than in the VinIV treated patients: 85€ versus 265€ . No major out-
patient cost differences were reported on paramedical care, lab tests, imageries and 
medical visits. However, ambulatory costs (1,125€ vs 129€ ) and other drugs (287€ 
vs 85€ ) were higher for VinO chemotherapy. On the contrary, in-patient cost were 
found higher in VinIV patients (2,699€ versus 1,360€ ). Overall, patients treated with 
VinO (3,122€ ) cost less than VinIV (3,284€ ), resulting in a saving of 81€ per cycle. If 
about 10,000 cycles were to be administered in France, savings related to VinO would 
amount to 0.86m€ . ConClusions: This survey demonstrated that VinO prescribed 
in daily practice is associated with reduced hospitalization in comparison to its 
IV form and decreased cost to the Sécurité Sociale, for the same level of efficacy. 
Policies aimed at reinforcing the use of oral chemotherapy might result in saving 
to National Health Care Services.
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objeCtives: The objective of this study of breast cancer patients enrolled in the 
EMILIA clinical study was to compare costs of treating patients with either ado-
trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C). Methods: 
All healthcare resource utilization (HCRU) and study drug costs for the EMILIA clini-
objeCtives: To determine the most cost-effective treatment scheme for tran-
sitional cell carcinoma of the urothelial tract (TCCU) in second line through the 
comparison of vinflunine+ best supportive care (BSC) and BSC from a payer per-
spective. Methods: Cost-effectiveness and budget impact analysis were per-
formed. Efficacy data came from phase III clinical trial. The economic perspective 
was the one of the Russian national health system. Results are expressed in RUB, 
year 2015. Sensitivity analysis were conducted to check the robustness of our find-
ings. Results: ICER was calculated: 1 114 504 RUB/18 541 EUR life-year gained (LYG). 
Budget impact analysis revealed that, a treatment with vinflunine+BSC required 
additional costs: 332 944 RUB/5 539 EUR for a 3-cycle treatment course. According 
to the budget impact analysis, shifting from a vinflunine+BSC treatment to BSC 
alone requires additional costs of 241 384 391 RUB/4 015 711 EUR for TCCU patients 
after failure of a prior platinum-containing regimen in Russia for a fulltreatment 
course. ConClusions: Vinflunine+BSC is cost-effective, as ICER does not exceed 
the willingness-to-pay threshold of Russia, which equals 1 481 749 RUB/24 651 EUR. 
And this ICER per LYG is lower than the ones calculated for the other chemothera-
pies used in oncology.
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objeCtives: To conduct a budget impact and cost effectiveness analysis of 
ferric carboxymaltose in Russian patients with colon cancer in preoperative 
period. Methods: Based on literature data (Salvadora Delgado et al. 2013, Efficacy 
of Preoperative Administration of Ferric Carboxymaltose in Colon Cancer Patients 
and Anemia) we created a pharmacoeconomic model of intravenous iron therapy 
in patients with colon cancer and anemia. The study included two groups (100 
patients each), treated with ferric carboxymaltose and placebo, respectively. The 
model included costs of medications, hospitalization and transfusions. Results: 
Total costs were 10 679 174 rub. in placebo group and 10 518 707 rub. in ferric car-
boxymaltose group. The costs of blood transfusion were 3.9 times lower in carboxy-
maltose group compared to control (placebo group); hospitalization in this group 
lasted shorter, which reduced costs 1.23 times (4 155 000 rub. and 5 100 000 rub., 
respectively). The role of cost effectiveness ratio in terms of clinical result without 
clinical complications was 132 644,50 for ferric carboxymaltose and 145 294,90 in 
placebo group. ConClusions: The application of ferric carboxymaltose in patients 
with colon cancer is justified by the comparative effectiveness estimated in budget 
impact analysis, and allows reducing costs in healthcare system.
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objeCtives: Non-Hodgkin’s lymphomas (NHLs) account for 90% of all lympho-
mas. Rituximab intravenous (IV) infusion represents a widely used therapeutic 
option against CD20-positive lymphomas. Recently, the therapeutically equivalent 
subcutaneous (SC) formulation was made available. Taking into account that SC 
formulations can result in resource and cost savings compared to IV forms of 
the same medication, this study aims to perform a cost-minimization (CMA) and 
budget-impact analysis (BIA) of introducing and switching to Rituximab SC injec-
tion for the treatment of NHLs in Greece. Methods: A questionnaire-based sur-
vey to a group of clinical practitioners that manage NHL patients formed the basis 
of the analyses. The collected data captured the resources used for the preparation 
and administration of Rituximab SC and/or IV, namely staff times, medications, 
consumables and overheads during patient stay. A CMA compared the costs of 
Rituximab SC versus IV by estimating the total cost/patient over the full course 
of treatment and the BIA estimated the impact of different penetration scenarios 
of the two formulations over a 3-year period. Calculations followed a third party 
payer perspective, according to the health system’s official price lists. Results: 
Results indicated that the SC administration provided a 77% reduction in the 
average time the nurses spent on a patient and a reduction of 90% in the time 
that the infusion chair was occupied. The average administration cost per patient 
over the full course of treatment was 13.627€ and 14.245€ for the SC and the 
IV, respectively. Budget savings for the first year of full implementation of SC 
administration was 618.708€ for a population of 1.000 patients. ConClusions: 
The outcomes suggest that the introduction of Rituximab SC in the treat-
ment of NHL could provide the grounds for efficient resource allocation within 
the hospital setting, as well as increasing maximum capacity to facilitate 
demand.
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objeCtives: There have been several recent product launches for the treatment 
of metastatic castration resistant prostate cancer (mCRPC). The aim of this study 
was to assess the cost of mCRPC treatments across the EU5 (France, Germany, 
Italy, Spain, UK) in relation to overall survival (OS), to determine if payers equally 
value the cost/ OS month for mCRPC treatments. Methods: Median OS (total and 
gain vs control arm) and average treatment duration were extracted from Phase III 
trial data for Zytiga, Xtandi, Jevtana, and docetaxel for each approved indication. 
Launch prices were extracted from publically available sources. The cost/total OS 
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objeCtives: To critically analyse radiotherapy cost studies published over the last 
35 years. Methods: We conducted a comprehensive and systematic review of the 
literature searching for radiotherapy cost calculation studies on PubMed (Medline) 
and Embase databases and in the grey literature. The searches yielded 1327 unique 
entries that were evaluated against the following selection criteria: actual medical 
cost, external beam radiotherapy (EBRT), clear description of the cost calcula-
tion method. The review for compliance with the criteria was conducted in three 
phases: title; abstract and then full manuscript. Results: Since 1981, 50 studies 
satisfied our selection criteria. Any perspective, e.g. societal, institutional, was 
considered acceptable as long as the institutional resources ‘cost of radiotherapy 
was presented. Cost assessments of EBRT were conducted within a full economic 
evaluation framework (5 studies: 2 CEA, 2 CUA, and 1 CBA), cost analysis (24), cost 
description (18) and investment analysis (3). The scope of the selected studies 
ranged from comprehensive medical cost of radiotherapy including the depart-
ment’s overhead (20), to average cost specific to one pathology and/or treatment 
modality (25) to task-specific costs (7) e.g. shielding. Costs were computed per 
fraction and/or field (20), per treatment and/or patient (27) and specific to a treat-
ment’s process step (3). Costing methodologies ranged from detailed micro costing 
(13) to activity-based costing (5) to time-driven activity-based costing (2). Besides 
these established accounting methods, numerous “home-made” approaches were 
observed (23) and some studies didn’t state their method (7). ConClusions: 
Due to heterogeneity both in methodology, input factors and paucity in costing 
method’s reporting, it was not possible to compare the cost estimates provided 
by these various studies. This comprehensive literature review of radiotherapy 
cost studies highlights the need for such studies to be conducted according to 
conventional accounting approaches and with rigor in the reporting of cost inputs 
and methodology.
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objeCtives: The extended-release oxycodone hydrochloride is an opioid with 
similar action to morphine with proven efficacy in moderate to severe pain man-
agement. This study aims to develop a cost analysis of extended-release oxycodone 
versus morphine in an “if necessary” regime for cancer-related pain management, 
from the Brazilian public and private healthcare systems perspectives. Methods: 
A decision model was developed to analyze the following strategies: group 1, 20 mg 
of extended-release oxycodone; group 2, 10 mg of extended-release oxycodone; 
and group 3, placebo. Efficacy data were obtained from Zhou e Wang, 2012. Direct 
costs were obtained from official price lists. Time horizon was determined through 
the hospital discharge period, and discount rates were not applied. Univariate sen-
sitivity analysis was performed to evaluate different hospital categories. Results: 
Total costs were 1,103 BRL, 1,071 BRL and 1,214 BRL per patient treated, from the 
public perspective, in groups 1, 2 and 3, respectively. The addition of oxycodone 
(10 and 20 mg) to the treatment reduced hospitalization stay, leading to savings 
of up to 143 BRL per patient, or a 12% reduction in total hospitalization cost. 
Total costs were 2,372 BRL, 2,367 BRL and 2,759 BRL per patient treated, from 
the private perspective, in groups 1, 2 and 3, respectively. The addition of oxyco-
done to treatment can lead to savings of up to 392.66 BRL per patient, a reduc-
tion about 14% of the total treatment cost during hospitalization. The univariate 
sensitivity analysis showed consistent results. ConClusions: The inclusion of 
extended-release oxycodone can lead to a reduction in total costs related to pain 
treatment in patients with cancer, which would lead to resource savings for the 
payer.
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objeCtives: Only a few international studies give valid information about cost 
of Best Supportive Care (BSC) of patients with unresectable advanced or meta-
static non-small-cell lung cancer (NSCLC). The aim of this non interventional 
study was to compare the results of these studies with data collected under 
real-world-conditions in 26 oncological practices in Germany. Methods: Data 
collected from oncological practices in Germany contain information about the 
entire course of treatment including the medication of primary disease, radio-
therapy, number of outpatient specialist visits, length of hospitalisation, type 
and number of diagnostic and laboratory procedures. In addition, four different 
studies from USA, Scotland, Great Britain and the Netherlands with information 
about cost of BSC were examined. To compare these studies with data from the 
oncological practices, the results were transferred into the german reimbursement 
systems for health care services. The calculation for annual cost of treatment is 
based on methods of the Institute for Quality and Efficiency in Healthcare (IQWiG) 
in Germany. Results: 509 patients with NSCLC from 26 oncological practices 
throughout Germany were included in the statistical and cost´s analysis. Patients 
cal trial population were included in the estimation of total cost. HCRU costs were 
estimated using the mean reimbursed amounts from a cohort of breast cancer 
patients from the Truven Health Marketscan database. Study drug costs were esti-
mated using the unit wholesale acquisition cost for T-DM1 and L+C. Monthly costs 
were calculated by dividing the total cost by the observed survival time (in months). 
Total costs were evaluated using the Kaplan Meier Sample Average (KMSA) estima-
tor to account for differences in the length of follow-up and censoring between 
trial arms. Results: In the EMILIA clinical trial, median overall survival was 30.9 
months with T-DM1 (n= 495) versus 25.1 months with L+C (n= 496) after a median of 
19 months follow-up. No differences were observed in the monthly cost per-patient 
between T-DM1 ($7,151, 95% confidence interval [CI]: $6,753 - $7,550) and L+C ($7,909, 
95% CI: $5,095 - $10,723). The KMSA mean total costs were $331,083 (95% CI: $152,238 
- $506,128) and $264,421 (95% CI: $133,143- $412,927) in the T-DM1 and L+C arms, 
respectively. Hospitalization costs were lower among the T-DM1 arm ($9,634, 95% CI: 
$6,394 - $12,873) than the L+C arm ($11,286, 95% CI: $6,216 - $16,357). ConClusions: 
Although the mean total costs were higher for T-DMI because of longer survival rela-
tive to L+C, the average monthly costs of treating patients with T-DM1 were similar 
to L+C. This study, along with the 5.8-month survival benefit, supports the potential 
value of T-DM1 for the treatment of HER2+ metastatic or locally advanced breast 
cancer.
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objeCtives: To evaluate and compare surgical parameters and costs associated 
with robotic and laparoscopic surgery for colorectal cancer over 5-years (2009-2014) 
in a single Italian centre. Methods: From 2009 to 2014 data about laparoscopic 
(LAP) and robotic (ROB) assisted colorectal cancer procedures performed in General 
Surgery, University Hospital of Pisa were collected. Operating time and length of 
stay were evaluated as surgical parameters and costs included fixed and variable 
items. Amortised cost of the robot and laparoscopic instrument and amortised 
cost of robot maintenance per intervention were considered among fixed costs. 
Variable costs included costs of dispensable equipment, cost of operating room 
personnel per time and costs of length-of-stay. Over the 5-years period surgical 
parameters and costs associated with LAP and ROB were analysed using descriptive 
statistics and compared between groups by independent T-test and Mann-Whitney 
test. Generalized linear models were used to assess the independent effect of type 
of surgery and time. Results: A total of 25 laparoscopic (LAP) and 50 robotic (ROB) 
procedures were evaluated. Overall median operating time was significantly higher 
in LAP (270 min vs 312.5 min, P= 0.006) and regression analysis showed a borderline 
significant interaction effect between type of surgery and years (P= 0.058) suggesting 
a significant reduction of operating time in ROB but not in LAP. Hospital-stay did 
not differ between groups (P= 0.567). Overall mean costs associated to LAP varied 
between 8,612±2,733 Euros in 2009 to 10,827±5,038 Euros in 2013. For ROB mean costs 
were 12,966±1,115 Euros in 2010 to 11,933±1,753 Euros in 2014. Regression analysis 
outlined significant greater costs for ROB (P-value< 0.001) without differences over 
time. ConClusions: Robotic surgery for colorectal cancer carries out significant 
greater costs and operating time compared to laparoscopic surgery. There is weak 
evidence of improvement in the exploitation of ROB procedures without significant 
consequences on costs at present.
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objeCtives: Patients undergoing HCT are at risk for infections, especially dsDNA 
viral infections (cytomegalovirus, BK Virus, Epstein-Barr Virus, HHV-6, herpes sim-
plex, herpes zoster, and adenovirus), for which there are limited viable preventative 
pharmacotherapies. Our objective was to compare direct medical costs reimbursed 
by health insurers following HCT for patients with dsDNA viral infection versus 
those without infections. Methods: MarketScan Research Databases were used to 
identify patients with a first (index) procedure code for HCT between 01-July-2009 
and 30-June-2014. Eligible patients were required to have 365 days of health plan 
enrollment prior to HCT to understand baseline factors. Reimbursements were 
tabulated for up to 365 days post-transplant; univariate Wilcoxon tests compared 
reimbursements for patients with at least one dsDNA infection versus patients 
with no dsDNA infection. Results: The cohort included 6,553 HCT patients with 
no dsDNA viral infection (2,111 [32%] allogeneic, 4,442 [68%] autologous) and 1,275 
patients with at least one dsDNA viral infection (924 [72%] allogeneic, 351 [28%] 
autologous). Mean (SD; IQR) reimbursements for the 365 days post-transplant were 
$218,151 (SD= $209,717; IQR= $94,873-$276,992) for HCT recipients without dsDNA 
infections versus $470,784 (SD= $467,557; IQR= $193,854-$588,019; p= 0.0001) for 
those with any dsDNA viral infection. Among allogeneic HCT recipients, reim-
bursements were higher. Mean (SD; IQR) costs post-transplant for allogeneic HCT 
recipients without infection were $320,320 (SD= $278,388; IQR= $ 53,191-$405,450) 
versus $551,664 (SD= $503,913; IQR= $261,318-$654,483; p< 0.0001) for patients with 
any dsDNA viral infection and $999,010 (SD= $822,223; IQR= $449,033-$1,410,000) 
for patients with adenovirus infection. Adenovirus infection represented 4.5% 
of all dsDNA viral infections. ConClusions: Patients who experience dsDNA 
viral infection following HCT have a higher burden of reimbursement com-
pared to those without such infections. dsDNA virus infections are most com-
mon and more costly in allogeneic HCT recipients. Measures to prevent dsDNA 
viral infection following HCT could result in cost savings and improved patient 
outcomes.
